Article
Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
European urology focus - 1 Sept 2019
Hiew Kenneth, Hart Claire A, Ali Adnan, Elliott Tony, Ramani Vijay, Sangar Vijay, Lau Maurice, Maddineni Satish, Brown Mick, Clarke Noel
Abstract excerpt
BACKGROUND: Docetaxel chemotherapy is a standard of care for metastatic castrate-resistant prostate cancer (mCRPC): 40-50% of patients achieve a biochemical response. However, there is a lack of response predictive biomarkers. OBJECTIVE: To assess lactate dehydrogenase (LDH) as a docetaxel response biomarker in mCRPC and to examine the association of LDH with genomic alterations in primary diagnostic biopsies....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.